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Abstract
Introduction: Obstructive Sleep Apnea (OSA) is a major risk factor for cardiovascular disease. The goal of this study was to
demonstrate whether the use of CPAP produces significant changes in the heart rate or in the heart rate variability of
patients with OSA in the first night of treatment and whether gender and obesity play a role in these differences.
Methods: Single-center transversal study including patients with severe OSA corrected with CPAP. Only patients with total
correction after CPAP were included. Patients underwent two sleep studies on consecutive nights: the first night a basal
study, and the second with CPAP. We also analyzed the heart rate changes and their relationship with CPAP treatment,
sleep stages, sex and body mass index. Twenty-minute segments of the ECG were selected from the sleep periods of REM,
no-REM and awake. Heart rate (HR) and heart rate variability (HRV) were studied by comparing the R-R interval in the
different conditions. We also compared samples from the basal study and CPAP nights.
Results: 39 patients (15 females, 24 males) were studied. The mean age was 50.67 years old, the mean AHI was 48.54, and
mean body mass index was 33.41 kg/m
2 (31.83 males, 35.95 females). Our results showed that HRV (SDNN) decreased after
the use of CPAP during the first night of treatment, especially in non-REM sleep. Gender and obesity did not have any
influence on our results.
Conclusions: These findings support that cardiac variability improves as an acute effect, independently of gender or weight,
in the first night of CPAP use in severe OSA patients, supporting the idea of continuous use and emphasizing that
noncompliance of CPAP treatment should be avoided even if it is just once.
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Introduction
Obstructive Sleep Apnea (OSA) is considered a cardiovascular
risk factor, which increases the likely of suffering stroke, congestive
heart failure, arterial hypertension, pulmonary hypertension,
coronary artery disease, cardiac arrhythmias, and acute myocar-
dial infarction [1–6]. Although OSA has been associated with each
of these diseases, the exact etiopathogenic mechanisms are unclear
for most of these disorders. Among many of the systems affected by
OSA, changes in the autonomic nervous system (ANS) are
frequently studied [7,8].
In healthy people, sleep stages have a great impact on
sympathetic nervous system (SNS) activity, while the circadian
system predominantly affects the parasympathetic nervous system
(PNS) activity [9,10]. Even people with altered sleep patterns (e.g.
night shift workers) have an increased SNS activation [11]. In
OSA patients, both sympathetic and parasympathetic nervous
system control of the heart rate become unstable, with enhanced
parasympathetic tone during the apneas and hypopneas punctu-
ated with enhanced sympathetic nervous system activation
subsequent to the apneic events [12,13]. Although other
cardiovascular diseases, such as hypertension (which is a common
co-morbidity of OSA), are related to irregularities to both the PNS
and SNS, dysregulation in these systems is noted during the
daytime and nighttime in OSA patients even without evidence of
cardiovascular diseases [14,15].
Since OSA causes irregularities in the SNS function, OSA has
been associated with an increased risk of cardiovascular events and
mortality [16]. Besides, OSA severity is also linked to disturbances
of PNS activity [17]. PNS activity is higher in non-REM sleep
(NREM), particularly in stage 2 sleep, as compared with REM
sleep. This increase in PNS activity during stage 2 can be seen in
healthy subjects, but is even more noticeable in OSA, suggesting
that increased parasympathetic activity is a consequence of
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during NREM [18,3].
One of the simplest non-invasive methods to monitor changes in
cardiovascular control is by measuring heart rate variability
(HRV), which can be defined as a physiological phenomenon
where the time interval between heart beats varies. It is measured
by the variation in the beat-to-beat interval. HRV reflects the
relationship between the PNS and SNS, which is a good predictor
of future cardiovascular problems [19]. HRV can be analyzed by
using a time-domain analysis which measures beat to beat intervals
(R-R, also known as NN intervals) [19]. The most commonly used
time-domain HRV measure is SDNN (the standard deviation of
all NN intervals). Changes and variability in heart rate are strongly
influenced by sleep stages, and for some authors these changes do
not differ significantly when comparing OSA and non-OSA
patients [20–22]. R-R intervals have been shown to be at their
highest in the early morning between the sleep and wake periods
[23]. R-R intervals have also been shown to steadily increase from
wake to non-REM sleep then decrease during REM sleep in
healthy subjects [24]. Changes in the variances in R-R intervals
have been associated with the severity of OSA [25,26], although
other recent studies have argued that spectral analysis of HRV
may serve as a better method to determine of OSA severity [27].
Several studies have proposed the use of HRV as a simple and
cheap solution for the diagnosis of OSA, but the limitations of
current HRV analysis techniques and the multiple factors involved
in OSA make it unlikely that HRV analysis can substitute
polysomnogram (PSG) to diagnose OSA [28–31]
There exists evidence supporting the notion that CPAP
treatment, which is a common therapeutic modality for OSA
patients, affects HRV. Studies analyzing the effect of CPAP on
HRV in healthy canines found that CPAP significantly increases
cardiac output, heart rate and low frequency HRV (LF), while also
finding a decrease in high frequency HRV (HF), showing that
CPAP treatment can cause alterations in PNS and SNS in the
absence of a cardiac or sleep breathing disorders. [32]. In healthy
humans, no differences were found in PNS and SNS before or
after CPAP treatment, but significant changes in PNS and SNS
activity in non-apneic snorers were discovered [33,34]. Another
study showed an increased HRV after 1 month of CPAP
treatment in patients with heart failure. This finding is interesting
as low HRV is commonly seen in heart failure patients, and has
been correlated with increased mortality [35]. Two long-term
studies also showed improvement of HRV in OSA patient after
CPAP treatment [36,37]. While CPAP treatment improved HRV
during sleep, the improvements in HRV did not last during the
day [38].
Based on previous studies which showed a decreased HRV in
patients with OSA and other cardiovascular disorders [34,39,40]
using CPAP [41], our hypothesis it that very short-time period
treatment with CPAP may improve HRV by correcting
autonomic imbalance. Moreover, as patients with an increased
body mass index (BMI) have a greater apnea hypopnea index
(AHI), an increased amount of stage 1 sleep, decreased levels of
SatO2 and, partially, a lower slow wave sleep time [42], obese
patients may exhibit a different HRV pattern compared to those
without obesity. In addition, several studies have shown that OSA
is more common in men than women. Although the exact
mechanisms are unclear, differences in obesity, anatomy and
hormones are all though to play a role [43]. Thus, it is reasonable
to hypothesise that HRV in patients with OSA may be different in
men compared to women, as it has been shown that healthy
women have a higher vagal tone than men [44], and whether
there exist gender differences in the response to CPAP treatment
[45].
According to hypothesis stated above, our specific aims in this
study were: a) to HRV in patients with severe OSA; b) to
determine the effectiveness of CPAP treatment for improving
HRV in these patients in a very short time span (one night
treatment); c) to determine if obesity and gender play a role in
HRV in patients with severe OSA; and d) to discover if these
changes and the effect of CPAP vary depending on the different
sleep stages (REM, NREM, awake).
Methods
This was a single-center transversal retrospective study
involving patients with severe OSA (AHI.30). Subjects were
selected from the sleep database of the Sleep Unit of the University
Clinic of Navarra. Patients were either referred to the Sleep Unit
from other departments within the University Clinic of Navarra
(Neurology, Pulmonology, ENT, etc.) or from other hospitals of
Spain. Most patients were referred because of primary complaints
of snoring, daytime somnolence, restless sleep or other symptoms
suggesting sleep apnea. Before PSG studies, all patients filled a
questionnaire to determine clinical relevant data including current
medications, current medical problems, alcohol, tobacco and
recreational drugs consumption, Epworth scale, height and
weight.
Inclusion and exclusion criteria
Inclusion criteria included: (I) Severe OSA, defined as 30 or
greater apneas and hypopneas per hour of sleep (AHI.30), (II)
age range of 30–60 years old, (III) complete reversal of OSA
during second PSG performed with CPAP treatment, and (IV)
subjects who did not smoke, drink alcohol and did not consume
recreational drugs.
Exclusion criteria included: (I) Atrial fibrillation and other
cardiac arrhythmias; (II) myocardial ischemia, cardiomyopathy or
myocardial infarction; (III) recent major surgery; (IV) cardiac
pacemaker; (V) history of cerebrovascular disease; (VI) psychiatric
disorders; (VII) other sleep disorders such as periodic limb
movement disorder (PLMD), restless limb syndrome (RLS) or
narcolepsy; (VIII) thyroid or other endocrine diseases, including
diabetes mellitus; and (IX) treatment with antiarrhythmic,
anticholinergic or antidepressant medications.
Sleep Study, Measurements & CPAP Procedure
OSA was diagnosed based on a preliminary overnight PSG
study. PSG studies were performed using Lamont amplifiers, 20
bit, 32 channels with 200 Hz sampling rates and dedicated inputs
for EEG, single-lead ECG (lead II), tibial and chin EMG, oronasal
flow, respiratory effort, oxymetry, heart rate and body position.
CPAP machines were regular Resmed CPAP (California, USA).
Sleep stages, hypopneas, apneas and arousals were scored using
the standard recommended American Academy of Sleep Medicine
(AASM) scoring criteria [46]. Following the baseline study,
subjects underwent a second PSG study to treat the OSA using
the suitable CPAP pressure. The CPAP pressure was calculated
according to neck circumference (NC), body mass index (BMI) and
IAH, following the widely used equation previously described by
Hoffstein et al: P=(0.166BMI)+(0.136NC)+(0.04+AHI)25.12
[47] Only patients with total correction of apneas with CPAP
were included. CPAP treatment was considered successful if AHI
in the night with CPAP was less than 10 and the lowest oxygen
value was higher than 89%.
Heart Rate Variability in Sleep Apnea
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In order to assess changes in HRV from the patient’s baseline
study to their second study with CPAP treatment, 20-minute
concatenated segments were selected from the sleep periods of
REM, non-REM (NREM) and awake (WAKE), avoiding
awakenings and artifacts. Although concatenated segments were
taken, , an attempt was made to select consecutive or relatively
close sleep stages in the selection process for REM and NREM
segments, based on previous studies that show that HRV varies
significantly throughout the night [19]. Most of the selected REM
segments were not from the first quarter of sleep, but exceptions
were made for certain CPAP studies which only consisted of one
REM cycle. NREM segments were taken from stage 3 and stage 2
sleep and were excluded if they occurred in the first quarter of the
night. Periods with ectopic cardiac beats and arousals were
excluded from analysis.
Sleep data in the form of digital files were collected using the
Stellate Reviewer software program. The sleep segments were
saved as text files from their digital recording in Stellate Reviewer
Version 6 (Stellate Inc., Montreal Canada), including the ECG,
airflow and SaO2 signals. The text file containing the sleep data
were converted into a Spike2 data file (S2R) using Spike 2 (version
6.02, Cambridge Electronic Design Limited, Cambridge UK).
The S2R files were then analyzed using an HRV analysis program
created through MATLAB (Mathworks Inc., Nattick Massachu-
setts, USA) by one of the authors (J.L.). Each ECG recording was
manually inspected to avoid abnormal QRS wave morphology,
movement artifacts, and to ensure that R-waves were correctly
marked by the HRV analysis program to allow an accurate
detection of R-R intervals.
The whole 20-minute segment was used to perform the analysis.
The HRV program analyzed the data using a linear, time-domain
analysis, which measures the mean and variance of the R-R
intervals. The following measures were recorded from the HRV
analysis program: a) Heart rate mean (R-R mean interval), b)
HRV (measured as the standard deviation of NN intervals for the
20-minute segments [SDNN]), c) Minimal SatO2, d) Mean SatO2,
e) Apnea duration, and f) Variance of SatO2 (Var. SatO2). Each of
these 6 components was assessed during the selected sleep periods
(WAKE, REM, NREM) in both the basal and CPAP study.
Comparisons of HRM, HRV and Var. SatO2 between the first
(basal study) and the second night (with CPAP) were performed.
Subgroups analysis comparing different sleep stages (WAKE,
REM and NREM), obese versus non-obese, and male versus
female were also performed.
Statistical analysis
All statistical tests were performed using SPSS version 15.0.1
(SPSS Inc., Chicago, IL, USA). To investigate the effect of CPAP
treatment by group, one-way ANOVA was performed. For
categorical (qualitative) data, the x2 test was used to check the
differences between the two groups. When the expected
frequencies were less than 5, Fisher’s exact test was performed.
For comparisons of two or more means, the analysis of variance
(ANOVA) was performed. When a significant result was obtained
in the ANOVA test, a post-hoc analysis (Scheffe ´’s test) was carried
out to perform multiple comparisons. In all cases, statistical
significance was defined as p,0.05. A multivariate test was
performed to test the effect of gender and obesity on CPAP
treatment. To evaluate the changes between NREM and REM, a
paired t-test was carried out.
Standard protocol approval
This study was approved by the Institutional Review Board
(IRB) of the University of Navarra. The IRB specifically waived
the need for consent of participants, as this was a retrospective
study. Data were anonymized by removal of direct identifiers from
the data file (a variable was removed when it was highly identifying
such as name, surname or place of birth; other variables which
were irrelevant for analytical purposes were also removed).
Results
Sample characteristics
Thirty-nine patients (15 females, 24 males) with a mean age of
50.67 years (51.7 in females, 50 in males), a mean AHI of 48.54
(45.01 in females, 50.75 in males), a mean weight of 97.47 kg
(100.5 in males, 92.52 in females), a mean height of 1.71 m (1.77
in males, 1.60 in females), and a mean body mass index (BMI) of
33.41 (31.83 in males, 35.95 in females) were included (Table 1
and 2). Comparisons between men and women revealed no
statistical differences in age, severity of apneas, duration of apneas,
number of oxygen desaturations per hour of sleep, minimal SatO2
and mean SatO2. Men were taller, and as the weight was similar,
they tended to have lower BMI, but the difference was not
significant. Twenty subjects were obese (BMI.30) and 6 had
morbid obesity (BMI.35).
Relationship between HR parameters in OSA with CPAP
treatment
The primary aim of this study was to determine how HRV in
OSA patients is affected after acute CPAP treatment, in a single
night of treatment. First we compared heart rate mean (HRM)
and HRV, considering all the patients and stages together. With
these data, no significant differences were seen in the HRM
when comparing the basal study to the CPAP study (p.0.05).
On the other hand, significant differences were seen when
comparing HRV before and after CPAP treatment (p,0.05). As
expected, significant differences did occur when comparing the
variation in SatO2 levels before and after CPAP treatment
(p,0.005). A summary of the results from this section is
presented in Table 3.
Table 1. Patients included in the study.
N Age ± SD (years) Height ± SD (m) Weight ± SD (kg) BMI ± SD (kg/m
2)
Male 24 50.7066.74 1.776.05 96.59618.32 30.7065.17
Female 15 51.7368.33 1.606.07 92.52621.99 35.9567.82
Total 39 51.4067.35 1.706.16 94.84619.77 32.9766.85
SD: Standard Deviation. BMI: Body Mass Index.
Men were taller than women. Women had a tendency to higher BMI but it was not significant. Age and AHI were similar.
doi:10.1371/journal.pone.0033769.t001
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Table 4 summarizes the results comparing HRM and HRV
between the sleep stages during basal and CPAP studies. First we
compared HRM and HRV in basal studies. HRM was higher in
wakefulness, but it was similar in non-REM and REM (73 bpm vs.
64 bpm vs. 63 bpm, F=7.598, p,0.005). In the CPAP studies,
HRM was higher in wakefulness (73 vs. 63 vs. 61, F=7.598,
p,0.005). However, HRV was only significantly lower in the non-
REM stage (0.490 ms) compared to wake (0.0837 ms) or REM
sleep (0.0610 ms, T=2.788, p,0.01).
Relationship of HRV with obesity and gender
A multivariable analysis was performed in order to study the
relationship between HRV and HRM and obesity and gender.
Only HRV tended to be higher in obese patients (F=3.848,
p,0.05). No other differences were seen when comparing HRV
parameters in all stages between obese and non-obese patients
(p.0.05). Table 5 shows how obesity did not play a significant
role when comparing HRM or HRV during WAKE, NREM and
REM stages. When differences between basal and CPAP studies
were incorporated to the analysis, there were no differences in any
of the parameters between basal and CPAP studies. When
comparing the differences of HRV components in the basal study
and CPAP study across the three sleep stages, no significant
differences were seen between the obese and non-obese groups
(p.0.05).
A multivariable analysis was also performed in order to notice
whether any significant relationship existed between HRV and
gender. The results are shown in Table 6. Globally, there were no
differences (F=1.877, p.0.06). Men had a higher HRM in all
stages, and higher HRV only in WAKE. These results were similar
in the basal and CPAP studies.
Discussion
In this work, we aimed to study HRV during arousal-free sleep
periods in a homogenous patient sample (free from medications,
co-morbidities and any other sleep disorders) to analyze acute,
very-short term, autonomic effects of CPAP treatment on severe
OSA (AHI.30), and its differences depending on gender and
obesity.
CPAP treatment has shown to improve HRV in OSA patients
[36,37,48] and HRV is considered a more sensitive parameter
than HRM to detect changes in ANS. Our results showed that,
even in the first night with CPAP, the HRM was similar to the
basal night but the HRV decreased significantly, considering all
patients and sleep stages. Only patients with total normalization of
the apnea index and oxygen values were included in the study;
therefore, this result may be regarded as highly significant.
Given that, according to previous research, HRV is a good
indicator of ANS activity, it is likely that CPAP treatment is able to
reduce cardiac autonomic dysfunction in a very short time span.
The results of this study also suggest that it may not be completely
necessary for researchers and clinicians to wait months in order to
see significant improvements in HRV.
Another of our aims was to see if the improvement of HRV was
limited to either REM or NREM. According to our results,
significant improvements in HRV were more relevant in NREM,
even though some improvements were seen in REM sleep after
CPAP treatment. A previous study suggests that increased PNS
activity during NREM may be a compensating mechanism to
SatO2 fluctuations, which REM sleep disrupts [18].
REM is a unique sleep stage from a physiological point of view
when compared to NREM sleep stages because the heart rate and
breathing rate are similar to WAKE. However, the results of this
study did not support this vision, although our findings may be a
consequence of the high severity of OSA and obesity seen in the
patientgroup.Thelack ofsignificantchanges inHRVinREM after
CPAP treatment could be explained by the REM interference
theory in PNS activity. The clinical implication of these results may
suggest that patients who suffer from OSA with apneas occurring
predominantly during REM sleep, may not enjoy the same
cardiovascular benefits compared to OSA patients whose apneic
episodesarescatteredbetween REMandNREM.However,further
studies are required to determine whether the unique properties of
REM sleep influence autonomic function in patients with OSA.
Table 2. Respiratory features of patients included in the study.
N AHI ± SD
Apnea
duration ± SD (s)
N6 of oxygen
desaturations per h
of sleep ± SD
Minimal
SatO2 ± SD (%)
Mean
SatO2 ± SD (%)
Male 24 49.80617.86 21.4566.69 14.55620.9 90.84610.48 95.2161.55
Female 15 45.01610.36 18 64.86 17.18614.94 88.8668.8 94.8561.07
Total 39 47.70615.11 19.9866.15 15.67618.39 80610.09 95.0661.59
AHI: Apnea-Hypopnea Index. SD: Standard Deviation. SatO2: Variance of Oxygen Saturation.
doi:10.1371/journal.pone.0033769.t002
Table 3. Differences between basal and CPAP studies in HRM, HRV and oxygen saturation.
Total R-R interval (HRM) HRV (ms) Var. SatO2
Basal (first night) 0.902660.068 (66.4 bpm) 0.067360.011 1.194660.5338
CPAP (second night) 0.928260.073 (64.6 bpm) 0.093560.022 0.385760.1078
F 4.064 4.064 47.680
p value 0.229 0.045 ,0.0001
CPAP: Continuous Positive Air Preassure. HRM: Heart Rate Mean. HRV: Heart Rate Variability. Var. SatO2: Variance of Oxygen Saturation.
doi:10.1371/journal.pone.0033769.t003
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to REM during CPAP studies. This result is similar to previous
studies in healthy individuals [24]. The decrease HRV from
NREM to REM was seen in basal studies, which suggests that
OSA may influence the variance of the heart rate, but does not
vary the natural change of overall beats per minute from NREM
to REM. The lack of change in HRM during the CPAP study
suggests that CPAP treatment lowers the variance of heart rate
during NREM, as well as eliminates the change in the heart rate
between NREM and REM.
Previous studiesshowed obese patients tohave lower variations in
total HRV [49]. Our results also showed significant differences in
HRV in obese patients during REM when compared to the non-
obese group in both CPAP and basal studies. From these results, it
seems plausible that CPAP treatment may improve HRV in obese
patients, sufficiently so as to resemble the improved HRV seen in
non-obese patients with CPAP treatment. In our study, another aim
wastostudytheeffects ofobesity onCPAP treatmentinsevereOSA
(AHI.30) patients, as CPAP treatment has shown to lower night
time blood pressure and increase SNS activity in OSA patients [50].
The results from our study showed that obesity does not influence
HRV or HRM during CPAP treatment when compared to non-
obese patients. Based on theseresults,obesity doesseem to influence
heart rate mean in WAKE and REM, but not enough to be
statistically significant. Therefore, from a clinical perspective,
additional or differential forms of treatment do not seem necessary
when combating ANS dysfunction in obese patients.
The final aim of our study was to determine the role of gender
in HRV during short-term CPAP treatment of severe OSA
(AHI.30) patients, as women with breathing disorders have been
shown to have increased SNS activity during NREM, and men
with breathing disorders have been shown to have lower PNS
activity during wake [51], and women with high AHI had low
SNS activation during REM [52]. Our results did show a
difference in HRV between men and women in wakefulness. In
addition, HRM was different in all the sleep stages. Our results
showed a significant difference in HRV and heart rate mean
between our male and female groups during wake. However, the
changes were similar in the basal and in the CPAP nights, which
suggests that gender does not influence the improvements seen in
ANS activity from CPAP treatment. Nevertheless, the absence of
statistical significance when assessing the effects of gender and
obesity on HRV may be a consequence of the small sample size of
our study, which is one of its limitations.
The main limitation of our study is a consequence of its
transversal nature. In these regard, there is a possibility that
changes in HRV during acute CPAP treatment may reflect a
normalization of the respiratory pattern or may be due to changes
in venous return secondary to the dramatic changes of
intrathoracic pressure that occur during the apneic event rather
than changes in cardiovascular control mechanisms. Thus, caution
must be used when analyzing our results, as the effect of OSA in
autonomic activity may perhaps more likely to be detected by
comparing HRV on the first night of treatment with a sleep study
on CPAP after weeks of treatment, and not with a single-night
study, such as the present one. We neither studied whether the
changes in HRV were associated with the severity of OSA, as we
only selected patients with an AHI.30. Moreover, we do not
provide data regarding the percentage of stage 2 and stage 3 sleep
in the NREM segments, in spite of the fact that several studies
show that ANS balance differs between these 2 stages. Finally, we
did not study frequency-domain measures (i.e. HF, LF, and VLF);
hence, further studies may be needed to understand our findings in
depth.
Table 5. Analysis of data in non-REM, REM and WAKE
between obese and non-obese groups.
Obese vs. Non-obese REM NREM WAKE
HRM F=3.294 F=6.846 F=3.472
p=0.07 p=0.011* p=0.067
T=2.980 T=0.464 T=25.289
HRV F=3.848 F=1.512 F=0.48
p=0.052 p=0.223 p=0.490
T=24.897 T=24.472 T=24.840
Var. SatO2 F=1.859 F=1.350 F=0.001
p=0.18 p=0.250 p=0.974
T=4.527 T=5.472 T=3.645
HRM: Heart Rate Mean. HRV: Heart Rate Variability. Var. SatO2: Variability in
Oxygen Saturation.
*Statistical significance.
doi:10.1371/journal.pone.0033769.t005
Table 4. Heart rate mean and variability in OSA and sleep
stages, in basal and CPAP studies.
WAKE Non-REM REM
HRM HRV (ms) HRM HRV (ms) HRM HRV (ms)
Basal 73* 0.0837 63 0.1060 64 0.0909
CPAP 71** 0.0919 62 0.0490*** 62 0.0610
T 20.656 20.530 20.944 2.283 1.565 1.565
p value 0.516 0.600 0.352 0.029 0.127 0.127
HRM: Heart Rate Mean. HRV: Heart Rate Variability.
Comparing basal and CPAP studies in the 3 situations, only HRV during non-
REM was found to be lower in CPAP studies compared to basal studies. In the
basal studies, HRM was higher in Wake (*) than in non-REM or REM. HRV was
similar in the three situations. In the CPAP studies, HRM (**) was also higher in
WAKE than in non-REM or REM. HRV was lower in non-REM (***), compared to
REM and wakefulness.
doi:10.1371/journal.pone.0033769.t004
Table 6. Analysis of the data in non-REM, REM and WAKE
between male and female groups.
Male vs. Female REM NREM WAKE
HRM F=13.157 F=5.021 F=4.311
p=0.001* p=0.029* p=0,042*
T=1.540 T=2.438 T=1.262
HRV F=3.509 F=3.426 F=6.124
p=0.066 p=0.069 p=0.016*
T=20.954 T=20.672 T=2.785
Var. SatO2 F=0.278 F=0.001 F=1.646
p=0.600 p=0.972 p=0.204
T=0.523 T=0.657 T=1.444
HRM: Heart Rate Mean. HRV: Heart Rate Variability. Var. SatO2: Variance of
Oxygen Saturation.
*Statistical significance.
doi:10.1371/journal.pone.0033769.t006
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cardiac variability improves as an acute effect, independently of
gender or weight, in the first night of CPAP use in severe OSA
patients. Thus, we think that the CPAP treatment should not be
delayed. Severe OSA patients should be advised that even a single
night without CPAP has changes in the cardiac rate, which are
corrected with CPAP. Hence, to use or not to use the CPAP for a
single night does matter.
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